The oversubscribed fund, which will have a trans-Atlantic focus, closed above the private equity healthcare specialist’s initial € 2 billion target after 17 months fundraising.

Global private equity healthcare specialist ARCHIMED announces the final closing of its fifth multi-asset fund, MED Platform II, on € 3.5 billion ($ 3.75 billion). Main fund commitments amount to € 3 billion with the remainder committed to a side vehicle for co-investment. The sum collected for the main fund represents a record for private equity buyout vehicles investing exclusively in healthcare industries, according to data from Preqin. The oversubscribed MED Platform II began fundraising in January, 2022 with an initial target of € 2 billion but raised its target (or “hardcap”) twice to accommodate investors and cope with rich deal-flow.

The MED Platform funds partner with category leaders in the European and North American mid-cap healthcare industries, buying majority stakes alongside family owners, founders and managers.

MED Platform II attracted new investors from all regions of the world on top of an investor re-up rate (from existing investors in MED Platform I) of almost 100 percent. Among the wide range of institutional investors and family offices investing in the fund, 40 percent come from Europe, 30 percent come from North America, and 30 percent are based elsewhere, especially in Asia. MED Platform II is targeting 14 investments versus the seven MED Platform I invested in.

Orous Capital is thrilled to have acted as advisor to the Middle East on the fundraising of MED Platform II.

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

About Orous Capital

Orous Capital is an independent fundraising advisory firm supporting European fund managers in expanding their investors' base across the GCC region. The firm assists European General Partners and GCC-based institutional Limited Partners through a large range of alternative assets (Private Equity, Venture Capital, Private Debt, Real Assets and Infrastructure). Orous Capital's relationships include the region's most prominent sovereign wealth funds, endowments, pension funds, funds of funds and a strong network of institutional family offices. Orous Capital's additional service areas include strategic partnerships advisory, assisting international companies in their external growth projects in the GCC region.

Public Relations Contact